share_log

Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target

Maxim Group Upgrades Galmed Pharmaceuticals to Buy, Announces $4 Price Target

Maxim Group 将Galmed Pharmicals升级为收购,宣布目标股价为4美元
Benzinga ·  2023/07/24 08:57

Maxim Group analyst Jason McCarthy upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Hold to Buy and announces $4 price target.

Maxim集团分析师杰森·麦卡锡将Galmed Pharmicals(纳斯达克股票代码:GLMD)从持有上调至买入,并宣布目标股价为4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发